Spectrum of genomic alterations inFGFR3: current appraisal of the potential role ofFGFR3in advanced urothelial carcinoma

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

(2016) Noura J. Choudhury et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma

(2016) Aditya Bagrodia et al.   JOURNAL OF UROLOGY

Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine

(2016) Felix Wezel et al.   UROLOGIA INTERNATIONALIS

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors

(2015) Richard M Bambury et al.   BMC CANCER

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

(2015) Jeffrey S. Ross et al.   CANCER

Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations

(2015) Leandro H. Gallo et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2

(2015) Stéphane Oudard et al.   EUROPEAN JOURNAL OF CANCER

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

(2015) Norma Palma et al.   EUROPEAN UROLOGY

Genomic Characterization of Upper Tract Urothelial Carcinoma

(2015) John P. Sfakianos et al.   EUROPEAN UROLOGY

FGFR3 Unliganded Dimer Stabilization by the Juxtamembrane Domain

(2015) Sarvenaz Sarabipour et al.   JOURNAL OF MOLECULAR BIOLOGY

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1

(2015) Y. Nakanishi et al.   MOLECULAR CANCER THERAPEUTICS

A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

(2015) Kurt Miller et al.   UROLOGIA INTERNATIONALIS

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

(2014) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

(2014) Matthew I. Milowsky et al.   EUROPEAN JOURNAL OF CANCER

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

(2014) Jaime Acquaviva et al.   MOLECULAR CANCER RESEARCH

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

(2014) J. S. Damrauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy

(2014) Nilda Gonzalez-Roibon et al.   UROLOGY

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

(2014) Elizabeth A. Guancial et al.   Cancer Medicine

Toward a Molecular Pathologic Classification of Urothelial Carcinoma

(2013) Gottfrid Sjödahl et al.   AMERICAN JOURNAL OF PATHOLOGY

Phase II study of everolimus in metastatic urothelial cancer

(2013) Matthew I. Milowsky et al.   BJU INTERNATIONAL

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

(2013) Gregory R. Pond et al.   BJU INTERNATIONAL

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy

(2013) A Necchi et al.   BRITISH JOURNAL OF CANCER

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

(2013) Roberto Pili et al.   Clinical Genitourinary Cancer

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

(2013) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

(2013) Jeffrey S Ross et al.   MODERN PATHOLOGY

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Oncogenic FGFR3 gene fusions in bladder cancer

(2012) Sarah V. Williams et al.   HUMAN MOLECULAR GENETICS

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

(2012) Andrea Necchi et al.   LANCET ONCOLOGY

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

(2012) V Chell et al.   ONCOGENE

Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma

(2012) David Lindgren et al.   PLoS One

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

Fibroblast growth factor receptor-3 in urothelial tumorigenesis

(2012) Gopa Iyer et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

The A391E mutation enhances FGFR3 activation in the absence of ligand

(2011) Fenghao Chen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer

(2011) Y. Dodurga et al.   GENETICS AND MOLECULAR RESEARCH

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma

(2011) Hikmat A Al-Ahmadie et al.   JOURNAL OF PATHOLOGY

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population

(2010) Khaldon Bodoor et al.   Cancer Epidemiology

Paths of FGFR-driven tumorigenesis

(2010) Victor D. Acevedo et al.   CELL CYCLE

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

(2010) Lucie C. Kompier et al.   PLoS One

Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

(2009) S. Kang et al.   MOLECULAR AND CELLULAR BIOLOGY

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

(2009) E di Martino et al.   ONCOGENE